- 1 Major Article submitted *to Journal of Infectious Diseases*:
- $rac{2}{3}$

3 **Regional differences in vaccine uptake and serological responses to vaccine and**  4 **circulating strains of H1N1 viruses among patients with confirmed influenza** 

- 
- 5 6 Ashley L. Fink<sup>1</sup>, Hsuan Liu<sup>1</sup>, Kathryn Shaw-Saliba<sup>1,2</sup>, Thomas Mehoke<sup>3</sup>, Jared Evans<sup>3</sup>, 6 , 7 , 2hen-Ying Liu<sup>4</sup>, Mitra Lewis<sup>2</sup>, Lauren Sauer<sup>2</sup>, Peter Thielen<sup>3</sup>, Kuan-Fu Chen<sup>4</sup>, Richard
- 7 Zhen-Ying Liu<sup>4</sup>, Mitra Lewis<sup>2</sup>, Lauren Sauer<sup>2</sup>, Peter Thielen<sup>3</sup>, Kuan-Fu Chen<sup>4</sup>, Richard<br>8 Rothman<sup>2</sup>, Sabra L. Klein<sup>1,5,6,\*</sup>, Andrew Pekosz<sup>1, 2, 7,\*</sup>
- 8 Rothman<sup>2</sup>, Sabra L. Klein<sup>1,5,6,\*</sup>, Andrew Pekosz<sup>1, 2, 7,\*</sup>
- $\frac{9}{10}$
- 10 1W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns<br>11 Hopkins Bloomberg School of Public Health. Baltimore. Maryland 21205 USA:
- 11 Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205 USA;<br>12 Pepartment of Emergency Medicine, Johns Hopkins University School of Med
- <sup>2</sup>Department of Emergency Medicine, Johns Hopkins University School of Medicine,<br>13 Baltimore, Marvland 21205 USA:
- 13 Baltimore, Maryland 21205 USA;<br>14 <sup>3</sup>Research and Exploratory Devel
- 14 <sup>3</sup>Research and Exploratory Development Department, Johns Hopkins Applied Physics<br>15 Laboratory, Laurel, Maryland 20723 USA;
- 15 Laboratory, Laurel, Maryland 20723 USA;<br>16 <sup>4</sup>Department of Emergency Medicine, Clin
- 16 4Department of Emergency Medicine, Clinical Informatics and Medical Statistics<br>17 Research Center, Keelung Chang Gung Memorial Hospital, Chang Gung Univer
- 17 Research Center, Keelung Chang Gung Memorial Hospital, Chang Gung University,
- 18 Keelung and Taoyuan City, 33302 Taiwan;<br>19 <sup>5</sup>Department of Biochemistry and Molecular
- 19 <sup>5</sup>Department of Biochemistry and Molecular Biology, The Johns Hopkins Bloomberg<br>20 School of Public Health, Baltimore, Maryland 21205 USA;
- 20 School of Public Health, Baltimore, Maryland 21205 USA;<br>21 <sup>6</sup>Department of International Health. The Johns Hopkins B
- <sup>6</sup>Department of International Health, The Johns Hopkins Bloomberg School of Public<br>22 Health, Baltimore, Maryland 21205 USA:
- 22 Health, Baltimore, Maryland 21205 USA;<br>23 Tepartment of Environmental Health and
- <sup>7</sup>Department of Environmental Health and Engineering, The Johns Hopkins Bloomberg<br>24 School of Public Health, Baltimore, Marvland 21205 USA.
- School of Public Health, Baltimore, Maryland 21205 USA.
- 
- 25<br>26 26 **Running title:** Antibodies to H1N1 influenza viruses (40 characters max)
- 27 **Key Words:** H1N1 influenza, human surveillance, neutralizing antibody, seasonal
- 28 influenza vaccine<br>29 **Manuscript statis**
- 29 **Manuscript statistics:**
- 30 **Abstract:**
- 
- 31 **Text: 3500 max (currently 3500)**  32 **Number of figures:** 4 (7 tables and figures max; 4 panels per figure)
- 33 **Number of tables:** 3 (can have up to 25 MB of online suppl info)
- 34 **References:**
- 35 **Financial support:** This work was supported by the NIH/NIAID Center of Excellence in
- 36 Influenza Research and Surveillance contracts HHS N272201400007C and HHS
- 37 N272201400006C.<br>38 **Disclosures:** The a
- **Disclosures:** The authors report no conflicts of interest
- 39<br>40
- 40 \*Correspondence:<br>41 Sabra L. Klein. Ph.
- 41 Sabra L. Klein, Ph.D., <u>sklein2@jhu.edu</u>, 410-955-8898<br>42 Andrew Pekosz. Ph.D., apekosz1@ihu.edu , 410-502-9
- Andrew Pekosz, Ph.D., [apekosz1@jhu.edu](mailto:apekosz1@jhu.edu), 410-502-9306
- 43

Fink et al. 2



of preexisting immunity in the population.

Fink et al. 3

 Influenza causes disease in the human population and the specific strain of virus that is circulating, the levels of preexisting immunity to circulating viruses, vaccine uptake, vaccine strain match to circulating virus strains, and the presence of mutations that modulate virus fitness all contribute to the magnitude of seasonal cases and disease severity [1, 2]. Other factors impact the susceptibility to influenza in a strain independent manner, including age, immune status, pregnancy, gender, and the presence of co-morbidities [2-4].

 The 2015-16 influenza season in the Northern hemisphere was dominated by H1N1 Influenza A virus, with significant differences in the number of cases and disease severity across different countries [5]. In contrast, East and Southeast Asia experienced a particularly strong influenza season [5]. Serological assays using ferret antiserum indicated circulating H1N1 viruses were antigenically similar to the 2015-16 vaccine strain [6-9]. Surveillance for influenza-like illness (ILI) in 2015-16 was performed in the Emergency Departments (ED) of Chang Gung Memorial Hospital (CGMH), Taipei, Taiwan and the Johns Hopkins Medical Institution (JHMI), Baltimore, Maryland. The influenza season in Taipei was more severe than in Baltimore and factors including differences in circulating virus strains, vaccination rates, serum neutralizing antibody levels after vaccination, antibody cross reactivity between vaccine and circulating strains, and levels of preexisting immunity contributed to the different influenza seasons at the two surveillance sites.

#### **Materials and Methods**

Fink et al. 4

### **Human sample collection and ethics**



### **Virus sequencing and phylogenetic analysis**

 Viral RNA isolation and sequencing was performed as previously described [10, 11] and the phylogenetic analysis was performed as previously described [12] by comparing the full-length nucleotide sequence of the hemagglutinin (HA) open reading frame from representative strains of all clades of H1N1 2009 pandemic viruses retrieved from the Global initiative on sharing all influenza data (GISAID). Trees were viewed and colored using FigTree and HA clades were identified by adding known clade references to these trees and identifying branches for the 6B, 6B.1, and 6B.2 clades. Clade 6B.1 was

Fink et al. 5



Fink et al. 6



Fink et al. 7

### **Serum neutralization assay**

Human or ferret serum was used in microneutralization assays using MDCK cells as

previously described [10]. The neutralizing antibody titer was calculated as the highest

- serum dilution that eliminated virus cytopathic effects in 50% of the wells.
- 

#### **Statistical analysis**

Serology data were analyzed with a 2-way ANOVA followed by pairwise multiple

comparisons or by 1-way ANOVA or students t-test. Fold change in antibody titers

between different virus strains and across different sites were analyzed by Chi-square

analysis. Virus replication kinetics were analyzed using a repeated measures 2-way

ANOVA. Clinical data in tables 1-3 were analyzed by Chi-square analysis.

 For multivariate analyses, the antibody titers were log transformed. All variables with *p* < 0.2 and beta coefficient > 0.1 in the bivariate linear regression were evaluated with multivariate linear regression with Allen-Cady backward selection procedure, with priority determined by clinical relevance and existing literature support. We adopted the Akaike's Information Criteria and the Chi-square goodness of fit test to evaluate the model fitness. Interaction check was performed to evaluate the potential effect modification between vaccination, antibody titers, and significant risk factors. Because of the relative small sample size, we further performed propensity score weighting modeling, in order to simultaneously adjust multiple confounders. Confounders considered to influence the causal relationship between vaccination and antibody titers were modeled to generate the propensity of vaccination, with the propensity score used

Fink et al. 8



- 
- **Results**

 Influenza surveillance was performed in the ED at JHMI and at CGMH from November 1, 2015 (week 44 of 2015) to April 30, 2016 (week 17 of 2016). The basic demographic and disease characteristics of patients reporting with ILI that were either confirmed to be infected (IAV+) or not (IAV-) in Baltimore (n=252) and in Taipei (n=245) are summarized in **Table 1**. In Baltimore, there was a racial difference, in which more Caucasian/white patients with ILI were IAV- (40.1%) than IAV+ (23.5%). For IAV vaccination in Baltimore, 50.3% of IAV- patients received the 2015-16 seasonal vaccine compared to 29.8% in the IAV+ group. The Baltimore IAV- population had significantly more patients with multiple co-morbidities (50.3%) than the IAV+ population (35.3%). There was also a greater number of IAV- patients with ILI admitted to JHMI hospitals (44.3%) than IAV+ patients (29.4%). In contrast, fewer differences were observed between the IAV+ and IAV- individuals with ILI from the Taipei population. Greater numbers of females as compared to males were present in the IAV+ group (65.5%) than the IAV- group (52.6%) in Taipei.

 Enrollment weeks for IAV+ individuals were plotted (**Figure 1A and 1B**). Influenza A virus activity was lower and peaked later (mid-March; **Figure 1A**) in the Baltimore population and was higher and peaked earlier (January-February; **Figure 1B**) in the

Fink et al. 9

- Taipei population which was representative of the overall IAV activity in each country [6, 7].
- 



Fink et al. 10



 The amino acid mutations in the HA protein of circulating virus strains were mapped on the H1 HA protein crystal structure (**Figure 2C**). Clade 6B.1 viruses were characterized by mutations S84N, S162N, and I216T (purple), with an amino acid residue 162 on the Sa antigenic site (blue). Amino acid 216, along the 220 loop of the receptor-binding domain was adjacent to the Sb antigenic site (pink). The I216T mutation may be a compensatory mutation as a result of the S162N mutation [21]. Clade 6B.2 viruses contained two HA1 mutations: V152T, adjacent to the Sa and Sb antigenic sites and V173I, near the Ca1 antigenic site (yellow). In addition to the mutations in HA1, 6B.2 viruses contained two mutations in HA2: E164G and D174E which were both on the surface of the HA stalk domain (**Figure 2C**). When compared to the vaccine strain A/Cal/7/09, both clade 6B.1 and 6B.2 viruses had 11 additional amino acid mutations (P83S, D97N, K163Q, S185T, S203T, A256T, K283E, I321V and HA2: E47K, S124N, and E172K), many of which were located on or near antigenic sites.

Fink et al. 11



 We compared individuals that received the 2015-16 seasonal influenza vaccine with 261 those that did not across the two surveillance sites. Although receipt of the seasonal vaccine did not affect neutralizing antibody responses to the vaccine or circulating viruses in patients from Baltimore (**Figure 3B**), neutralizing antibody responses from Taipei patients were significantly greater in vaccinated compared to unvaccinated patients (**Figure 3C**). We conclude that geographic location and presumably the history of exposure to circulating and vaccine strains of influenza impact the antibody response induced by vaccination.

Fink et al. 12



 The antigenic characterization of IAV isolates is traditionally measured in HAI assays using strain specific, post-infection ferret antisera [24] and HAI assays showed ferret

Fink et al. 13



 Using an Allen-Cady modified stepwise multivariable regression model to control for confounding variables revealed increased age was consistently associated with lower titers (**Table 3**). In contrast, a significant association between age and neutralizing antibody titers in our univariate analysis was not observed (**Supplementary Figure 1**). Other factors that were associated with lower titers in different clades included male gender (A/Cal/7/09, 6B.1), steroid usage (6B), higher BMI (6B.2), being Asian (6B.1), and some socioeconomic factors. Although we did not observe gender differences in baseline neutralizing antibody titers in our univariate analysis (**Supplementary Figure 2**), previous studies have established that males tend to have significantly lower neutralizing antibody titers to influenza as compared with females [25]. Receipt of the influenza vaccine was associated with higher baseline neutralizing antibody titers to the A/Cal/7/09 vaccine strain virus and the clade 6B and 6B.2 circulating viruses. In a

Fink et al. 14

 propensity score weighting model, receipt of the influenza vaccine resulted in higher neutralizing antibody titers to all viruses except the clade 6B.1 virus. In the multivariable regression, when the variable "Asian" was removed, vaccination was still significantly associated with higher baseline neutralizing antibody titers, indicating that there could be a confounding effect between being Asian and receipt of the influenza vaccine. In the effect modification multivariable regression analysis, we found that vaccinated patients from Taipei had consistently higher antibody titers across different clades, except 6B.2 (**Table 3**). The observation that receipt of the influenza vaccine was associated with higher baseline neutralizing antibody titers to all viruses except the clade 6B.1 virus further confirms the recommendation to update the H1N1 vaccine virus to A/Mich/45/15, which is a clade 6B.1 virus.

#### **Discussion**

 This study illustrates differences in influenza activity, pre-existing influenza immunity, and virus strain circulation in the 2015-16 influenza season across surveillance sites located in Baltimore, Maryland and Taipei, Taiwan. We conclude that regional factors as well as host demographic variables, including age, gender, and BMI, may play important roles in modulating receipt of seasonal influenza vaccines, vaccine-induced immunity, and severity of influenza disease.

 The 2015-16 influenza season was characterized by increased H1N1 influenza cases in Taipei compared to Baltimore, with differences in the HA clades that circulated at each site, consistent with previous reports [26-28]. Clade 6B.2 viruses circulated in primarily

Fink et al. 15



individuals with no known influenza co-morbidities in Taipei compared to Baltimore,

indicating a greater degree of susceptibility in the population in Taipei, which is

supported by the overall lower vaccine rate and levels of neutralizing antibodies to

circulating human H1N1 present in that population. The overall lower antibody titers to

6B.1 viruses in Taipei were surprising given that antigenically related viruses have been

circulating globally since 2009. Vaccination, however, did not affect neutralizing

antibody titers in patients from Baltimore, perhaps due to higher levels of preexisting

H1N1 immunity in that population. These data suggest that regional differences in

influenza vaccine uptake and immune responses to vaccination are present and can

impact the overall susceptibility of the population to influenza virus infection.

Fink et al. 16



 We did not observe any relationship between neutralizing antibody titers and specific age-ranges [40-43], but this is most likely due to small sample sizes in most age groups. Although more females presented as IAV+, at least in Taipei, male gender, steroid use,

Fink et al. 17

 and higher BMI correlated with lower neutralizing titers, as these are associated with an impaired humoral immune response [44, 45].

 There are limitations of this study. Our acute influenza detection protocol does not include pediatric patients so we are unable to assess preexisting immunity and case numbers in age groups <18 years of age. Because only one surveillance site is used in each country, we are unable to capture any regional differences within the United States or Taiwan. Finally, the limited number of patients enrolled in our studies prevents us from assessing the significance of a number of clinical and demographic factors on influenza susceptibility and disease severity. Although seasonal influenza epidemics are global, regional differences in human populations can impact the number and severity of influenza cases most likely through different exposure histories to circulating and vaccine strains. Vaccine efficacy and preexisting immunity to vaccine and circulating strains should be characterized at the local, national, and global levels to achieve accurate and complete assessments of the

factors that impact influenza in any year.

Fink et al. 18

# 401<br>402

#### **Acknowledgements**

- We would like to thank the clinical coordinators at JHMI and CGMH who were
- responsible for the data and sample collection. We also thank Stacey Schultz-Cherry,
- Victoria Meliopoulos, and the St. Jude Center of Excellence in Influenza Research and
- Surveillance (CEIRS) for providing the ferret antisera. We thank Deena Blumenkrantz
- and Robert Stenzel for providing technical assistance in growing influenza viruses and
- Dr. Andrew Lane for providing hNEC cultures.

### **Funding**

- This work was supported by the NIH/NIAID Center of Excellence in Influenza Research
- and Surveillance contract HHS N2772201400007C (R.R., K.F.C., S.L.K and A.P.), T32
- AI007417 (A.L.F.), the Richard Eliasberg Family Foundation and the Research Center
- for Emerging Viral Infections from The Featured Areas Research Center Program within
- the framework of the Higher Education Sprout Project by the Ministry of Education
- (MOE) in Taiwan and the Ministry of Science and Technology (MOST), Taiwan MOST
- 109-2634-F-182-001 (Y.N.G.).

Fink et al. 19

### **Figure legends**

 **Figure 1. Numbers of Influenza A virus isolates defined by clades with enrollment dates in the two surveillance sites, Baltimore (JHMI) and Taipei (CGMH).** Samples collected from patients with influenza-like illness (ILI) between week 44 2015 (starting Nov 2015) and week 16 2016 (ending April 2016) were tested for influenza A viruses (IAVs) and the IAV+ samples were subtyped and clade-defined by deep sequencing. (A) JHMI, (B) CGMH. Enrollments at week 6 of 2016 in Taipei were paused due to the Chinese New Year holidays. **Figure 2. H1N1 HA phylogenetic analysis from clinical virus isolates.** Clinical nasal pharyngeal (NP) swabs or nasal washes (NW) of IAV+ patients from Baltimore (JHMI) and Taipei (CGMH) were used to sequence the HA gene segment by deep sequencing. (A) HA phylogenetic tree representing the 2015-16 H1N1 viruses from individuals at Baltimore (red) and Taipei (blue) along with the 2015-16 vaccine strain A/California/7/2009 (green) and the 2017-18 vaccine strain A/Michigan/45/2015 (green). Representative isolates for serology assays and growth analysis are highlighted in yellow. (B) Numbers of clinical virus isolates in clades 6B.1, 6B.2 and 6B were identified. (C) HA protein structure of the clade 6B.1 and 6B.2 viruses are shown on a H1 HA crystal structure of H1N1 virus (PDB:3LZG) using PyMOL. Antigenic sites Sa, Sb, Ca1, Ca2, and Cb are indicated [46]. Amino acids are used to defined 6B.1 (purple) and 6B.2 (pink) and other amino acid differences compared with A/California/7/2009 (dark green) are indicated. Enlarged 6B.2 head shows that aa173 (in pick spheres) is not on the surface of HA, and is under site Ca1 (in sticks). (D) Viruses isolated from

Fink et al. 20



Fink et al. 21



Fink et al. 22

### 484 **References**

- 485<br>486
- 486 1. Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol<br>487 **2018**; 16:60.
- 487 **2018**; 16:60.
- 488 2. Paules C, Subbarao K. Influenza. Lancet **2017**; 390:697-708.
- 489 3. vom Steeg LG, Klein SL. SeXX Matters in Infectious Disease Pathogenesis. PLoS Pathog<br>490 2016: 12:e1005374.
- 490 **2016**; 12:e1005374.
- 491 4. Vermillion MS, Klein SL. Pregnancy and infection: using disease pathogenesis to inform<br>492 vaccine strategy. NPJ Vaccines 2018: 3.
- 492 vaccine strategy. NPJ Vaccines **2018**; 3.
- 493 5. World\_Health\_Organization. Weekley epidemiological record Nos. 51/52. Vol. 91,<br>494 2016:601-24.
- 494 **2016**:601-24.
- 495 6. Davlin SL, Blanton L, Kniss K, et al. Influenza Activity United States, 2015-16 Season and 496 Composition of the 2016-17 Influenza Vaccine. MMWR Morb Mortal Wkly Rep 2016; 496 Composition of the 2016-17 Influenza Vaccine. MMWR Morb Mortal Wkly Rep **2016**;
- 497 65:567-75. 498 7. Taiwan\_CDC. Taiwan Influenza Express 2015-16 Flu Season 2016 Week 20. Available at:<br>499 https://www.cdc.gov.tw/En/File/Get/VCNkIvtT0iuP1vo1gIG89A. 499 https://www.cdc.gov.tw/En/File/Get/VCNkIvtTOiuP1vo1gJG89A.<br>500 8. Chambers C. Skowronski DM, Sabaiduc S. et al. Interim estimates
- 500 8. Chambers C, Skowronski DM, Sabaiduc S, et al. Interim estimates of 2015/16 vaccine<br>501 effectiveness against influenza A(H1N1)pdm09, Canada, February 2016. Euro Surveill
- 501 effectiveness against influenza A(H1N1)pdm09, Canada, February 2016. Euro Surveill<br>502 **2016**: 21:30168.
- 502 **2016**; 21:30168. 503 9. Komissarov A, Fadeev A, Sergeeva M, et al. Rapid spread of influenza A(H1N1)pdm09<br>504 viruses with a new set of specific mutations in the internal genes in the beginning of
- 504 viruses with a new set of specific mutations in the internal genes in the beginning of 505 2015/2016 epidemic season in Moscow and Saint Petersburg (Russian Federation).
- 505 2015/2016 epidemic season in Moscow and Saint Petersburg (Russian Federation).<br>506 Influenza Other Respir Viruses 2016; 10:247-53.
- 506 Influenza Other Respir Viruses **2016**; 10:247-53.
- 507 10. Ursin RL, Liu H, Powell HR, et al. Differential Antibody Recognition of H3N2 Vaccine and<br>508 Seasonal Influenza Virus Strains Based on Age, Vaccine Status, and Sex in the 2017-2018
- 508 Seasonal Influenza Virus Strains Based on Age, Vaccine Status, and Sex in the 2017-2018<br>509 Season. I Infect Dis 2020: 222:1371-82.
- 509 Season. J Infect Dis **2020**; 222:1371-82.
- 510 11. Zhou B, Donnelly ME, Scholes DT, et al. Single-reaction genomic amplification<br>511 accelerates sequencing and vaccine production for classical and Swine origin hum 511 accelerates sequencing and vaccine production for classical and Swine origin human<br>512 influenza a viruses. Journal of virology 2009; 83:10309-13.
- 512 influenza a viruses. Journal of virology **2009**; 83:10309-13.
- 513 12. Blumenkrantz DR, Mehoke T, Shaw-Saliba K, et al. Identification of H3N2 NA and PB1-<br>514 F2 genetic variants and their association with disease symptoms during the 2014-15
- 514 F2 genetic variants and their association with disease symptoms during the 2014-15<br>515 influenza season. bioRxiv 2020:2020.02.20.956979.
- 515 influenza season. bioRxiv **2020**:2020.02.20.956979.
- 516 13. Fischer WA, 2nd, King LS, Lane AP, Pekosz A. Restricted replication of the live<br>517 attenuated influenza A virus vaccine during infection of primary differentiated hu
- 517 attenuated influenza A virus vaccine during infection of primary differentiated human<br>518 nasal epithelial cells. Vaccine 2015; 33:4495-504.
- 518 nasal epithelial cells. Vaccine **2015**; 33:4495-504.
- 519 14. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of 520 influenza A virus from recombinant DNA. Iournal of virology 1999: 73:9679-82.
- 520 influenza A virus from recombinant DNA. Journal of virology **1999**; 73:9679-82.
- 521 15. McCown MF, Pekosz A. The influenza A virus M2 cytoplasmic tail is required for<br>522 infectious virus production and efficient genome packaging. Journal of virology 200
- 522 infectious virus production and efficient genome packaging. Journal of virology **2005**;
- 523 79:3595-605.<br>524 16. Klein EY, E
- 524 16. Klein EY, Blumenkrantz D, Serohijos A, et al. Stability of the Influenza Virus<br>525 Hemagglutinin Protein Correlates with Evolutionary Dynamics. mSphere 2018 525 Hemagglutinin Protein Correlates with Evolutionary Dynamics. mSphere **2018**; 3.
- 526 17. Broberg E, Melidou A, Prosenc K, et al. Predominance of influenza A(H1N1)pdm09 virus<br>527 eenetic subclade 6B.1 and influenza B/Victoria lineage viruses at the start of the 2015/16
- 527 genetic subclade 6B.1 and influenza B/Victoria lineage viruses at the start of the 2015/16<br>528 influenza season in Europe. Euro Surveill 2016; 21.
- 528 influenza season in Europe. Euro Surveill **2016**; 21.

Fink et al. 23

- 529 18. Santos KC, Silva DB, Sasaki NA, Benega MA, Garten R, Paiva TM. Molecular epidemiology<br>530 of influenza A(H1N1)PDM09 hemagglutinin gene circulating in Sao Paulo State, Brazil:
- 530 of influenza A(H1N1)PDM09 hemagglutinin gene circulating in Sao Paulo State, Brazil:<br>531 2016 anticipated influenza season. Rev Inst Med Trop Sao Paulo 2017; 59:e9.
- 531 2016 anticipated influenza season. Rev Inst Med Trop Sao Paulo **2017**; 59:e9.
- 532 19. European\_Centre\_for\_Disease\_Prevention\_and\_Control. Influenza virus characterisation<br>533 summary Europe, May 2016. Available at:
- 533 summary Europe, May 2016. Available at:<br>534 https://ecdc.europa.eu/sites/portal/files/ 534 https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/influenza-<br>535 yirus-characterisation-may-2016.pdf.
- 535 [virus-characterisation-may-2016.pdf.](https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/influenza-virus-characterisation-may-2016.pdf)<br>536 20. Bedford T, Neher R. Seasonal influe 536 20. Bedford T, Neher R. Seasonal influenza circulation patterns and projections for 2016-<br>537 2017. Available at:
- 
- 537 2017. Available at:<br>538 https://github.com 538 https://github.com/nextstrain/static/blob/master/content/reports/01-flu-vaccine-<br>539 selection/03-2016-september.md. 539 <u>selection/03-2016-september.md</u>.<br>540 21. Altman MO, Angel M, Košík I, et
- 540 21. Altman MO, Angel M, Košík I, et al. Hemagglutinin Glycan Clock Guides Human Influenza<br>541 A Virus Evolution. bioRxiv 2017.
- 541 A Virus Evolution. bioRxiv **2017**.
- 542 22. Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza<br>543 vaccines: Formulation and production strategies. Eur I Pharm Biopharm 2015: 94:251-
- 543 vaccines: Formulation and production strategies. Eur J Pharm Biopharm **2015**; 94:251-63.
- 544 23. Blanton L, Wentworth DE, Alabi N, et al. Update: Influenza Activity United States and<br>545 Worldwide, May 21-September 23, 2017. MMWR Morb Mortal Wkly Rep 2017; 66:1043-545 Worldwide, May 21-September 23, 2017. MMWR Morb Mortal Wkly Rep **2017**; 66:1043-
- 546<br>547
- 547 24. Stohr K, Bucher D, Colgate T, Wood J. Influenza virus surveillance, vaccine strain<br>548 selection, and manufacture. Methods Mol Biol 2012; 865:147-62.
- 548 selection, and manufacture. Methods Mol Biol **2012**; 865:147-62.
- 549 25. Engler RJ, Nelson MR, Klote MM, et al. Half- vs full-dose trivalent inactivated influenza<br>550 vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med
- 550 vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med<br>551 **2008**; 168:2405-14.
- 551 **2008**; 168:2405-14.
- 552 26. Clark AM, DeDiego ML, Anderson CS, et al. Antigenicity of the 2015-2016 seasonal H1N1<br>553 human influenza virus HA and NA proteins. PloS one 2017; 12:e0188267.
- 553 human influenza virus HA and NA proteins. PloS one **2017**; 12:e0188267.
- 554 27. Uda K, Shoji K, Koyama-Wakai C, et al. Clinical characteristics of influenza virus-induced<br>555 lower respiratory infection during the 2015 to 2016 season. I Infect Chemother 2018; 555 lower respiratory infection during the 2015 to 2016 season. J Infect Chemother **2018**;
- 556 24:407-13.
- 557 28. Zhao XN, Zhang HJ, Li D, et al. Whole-genome sequencing reveals origin and evolution of 558 influenza A(H1N1) pdm09 viruses in Lincang, China, from 2014 to 2018. PloS one 2020; 558 influenza A(H1N1)pdm09 viruses in Lincang, China, from 2014 to 2018. PloS one **2020**;
- 559 15:e0234869.<br>560 29. Blanton L,
- 560 29. Blanton L, Alabi N, Mustaquim D, et al. Update: Influenza Activity in the United States 561 During the 2016-17 Season and Composition of the 2017-18 Influenza Vaccine. MMWR<br>562 Morb Mortal Wkly Rep 2017; 66:668-76.
- 
- 562 Morb Mortal Wkly Rep **2017**; 66:668-76. 563 30. European\_Centre\_for\_Disease\_Prevention\_and\_Control. Influenza virus<br>564 characterisation, summary Europe, June 2017: Stockholm: ECDC, 2017.
- 564 characterisation, summary Europe, June 2017: Stockholm: ECDC, **2017**.
- 565 31. Neher RA, Bedford T. nextflu: real-time tracking of seasonal influenza virus evolution in<br>566 humans. Bioinformatics 2015: 31:3546-8.
- 566 humans. Bioinformatics **2015**; 31:3546-8.
- 567 32. Bedford T, Neher R. Seasonal influenza circulation patterns and projections for 2017-<br>568 2018. Available at: https://nextflu.org/reports/feb-2017/.
- 568 2018. Available at: [https://nextflu.org/reports/feb-2017/.](https://nextflu.org/reports/feb-2017/)<br>569 33. Pebody R. Warburton F. Ellis J. et al. Effectiveness of sea
- 569 33. Pebody R, Warburton F, Ellis J, et al. Effectiveness of seasonal influenza vaccine in<br>570 preventing laboratory-confirmed influenza in primary care in the United Kingdom:
- 570 preventing laboratory-confirmed influenza in primary care in the United Kingdom:<br>571 2015/16 mid-season results. Euro Surveill 2016; 21.
- 571 2015/16 mid-season results. Euro Surveill **2016**; 21.
- 572 34. Korsun N, Angelova S, Gregory V, Daniels R, Georgieva I, McCauley J. Antigenic and<br>573 genetic characterization of influenza viruses circulating in Bulgaria during the 2015/2
- 573 genetic characterization of influenza viruses circulating in Bulgaria during the 2015/2016<br>574 season. Infect Genet Evol 2017: 49:241-50.
- 574 season. Infect Genet Evol **2017**; 49:241-50.

Fink et al. 24

- 575 35. Garretson TA, Petrie JG, Martin ET, Monto AS, Hensley SE. Identification of human<br>576 vaccinees that possess antibodies targeting the egg-adapted hemagglutinin receptor
- 576 vaccinees that possess antibodies targeting the egg-adapted hemagglutinin receptor<br>577 binding site of an H1N1 influenza vaccine strain. Vaccine 2018; 36:4095-101.
- 577 binding site of an H1N1 influenza vaccine strain. Vaccine **2018**; 36:4095-101.
- 578 36. Raymond DD, Stewart SM, Lee J, et al. Influenza immunization elicits antibodies specific<br>579 for an egg-adapted vaccine strain. Nat Med 2016; 22:1465-9.
- 579 for an egg-adapted vaccine strain. Nat Med **2016**; 22:1465-9.
- 580 37. Liu F, Tzeng WP, Horner L, et al. Influence of Immune Priming and Egg Adaptation in<br>581 the Vaccine on Antibody Responses to Circulating A(H1N1)pdm09 Viruses After Influenz
- 581 the Vaccine on Antibody Responses to Circulating A(H1N1)pdm09 Viruses After Influenza<br>582 Vaccination in Adults. J Infect Dis 2018: 218:1571-81.
- 582 Vaccination in Adults. J Infect Dis **2018**; 218:1571-81.
- 583 38. World\_Health\_Organization. Recommended composition of influenza virus vaccines for 584 use in the 2017 southern hemisphere influenza season. Available at:
- 584 use in the 2017 southern hemisphere influenza season. Available at:<br>585 https://www.who.int/influenza/vaccines/virus/recommendations/
- 585 https://www.who.int/influenza/vaccines/virus/recommendations/2017 south/en/.<br>586 39. World Health Organization. Recommended composition of influenza virus vaccine 586 39. World\_Health\_Organization. Recommended composition of influenza virus vaccines for 587 use in the 2017-2018 northern hemisphere influenza season. Available at:
- 
- 587 use in the 2017-2018 northern hemisphere influenza season. Available at:<br>588 https://www.who.int/influenza/vaccines/virus/recommendations/2017
- 588 [https://www.who.int/influenza/vaccines/virus/recommendations/2017\\_18\\_north/en/.](https://www.who.int/influenza/vaccines/virus/recommendations/2017_18_north/en/)<br>589 40. Linderman SL. Chambers BS. Zost SI. et al. Potential antigenic explanation for atypical
- 589 40. Linderman SL, Chambers BS, Zost SJ, et al. Potential antigenic explanation for atypical<br>590 H1N1 infections among middle-aged adults during the 2013-2014 influenza season.
- 590 H1N1 infections among middle-aged adults during the 2013-2014 influenza season.<br>591 Proceedings of the National Academy of Sciences of the United States of America 201 591 Proceedings of the National Academy of Sciences of the United States of America **2014**;
- 592 111:15798-803.
- 593 41. Flannery B, Smith C, Garten RJ, et al. Influence of Birth Cohort on Effectiveness of 2015-<br>594 2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza
- 594 2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza<br>595 A(H1N1) Virus in the United States. I Infect Dis 2018: 218:189-96.
- 595 A(H1N1) Virus in the United States. J Infect Dis **2018**; 218:189-96. 596 42. Skowronski DM, Chambers C, Sabaiduc S, et al. Beyond Antigenic Match: Possible Agent-<br>597 Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During
- 597 Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During<br>598 the 2015-2016 Season in Canada. J Infect Dis 2017; 216:1487-500.
- 598 the 2015-2016 Season in Canada. J Infect Dis **2017**; 216:1487-500.
- 599 43. Skowronski DM, Chambers C, Sabaiduc S, et al. A Perfect Storm: Impact of Genomic<br>600 Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 201
- 600 Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-601 2015 Season. Clin Infect Dis 2016; 63:21-32.
- 601 2015 Season. Clin Infect Dis **2016**; 63:21-32.
- 602 44. Sheridan PA, Paich HA, Handy J, et al. Obesity is associated with impaired immune<br>603 response to influenza vaccination in humans. Int J Obes (Lond) 2012; 36:1072-7.
- 603 response to influenza vaccination in humans. Int J Obes (Lond) **2012**; 36:1072-7. 604 45. Klein SL, Pekosz A. Sex-based biology and the rational design of influenza vaccination 605 strategies. J Infect Dis 2014; 209 Suppl 3:S114-9.
- 605 strategies. J Infect Dis **2014**; 209 Suppl 3:S114-9.
- 606 46. Krause JC, Tumpey TM, Huffman CJ, et al. Naturally occurring human monoclonal
- 607 antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. Journal of virology 2010; 84:3127-30.
- 608 virology **2010**; 84:3127-30.
- 609

# **Figure 1**

![](_page_24_Figure_1.jpeg)

**Enrollment Date (weeks 2015-2016)**

# **Figure 2**

 $\frac{1}{0.003}$ 

![](_page_25_Figure_1.jpeg)

**Vaccine strains** References

**Collection sites: Baltimore Taipei** 

## **B**

![](_page_25_Picture_140.jpeg)

6B.2

![](_page_25_Figure_7.jpeg)

![](_page_26_Figure_0.jpeg)

# **Figure 4**

![](_page_27_Figure_2.jpeg)

![](_page_28_Picture_0.jpeg)

![](_page_28_Figure_1.jpeg)

# **Supplementary Figure 2**

**1**

![](_page_29_Figure_1.jpeg)

**A/Cal/7/09 6b.1 6b.2 6b**

**H1N1 virus strains**

![](_page_29_Figure_2.jpeg)

![](_page_30_Picture_367.jpeg)

#### **Table 1. Patient characteristics at the two geographic locations, Baltimore and Taipei.**

![](_page_31_Picture_245.jpeg)

#### **Table 2. Clinical and demographic characteristics of H1N1 IAV-infected patients at Baltimore and Taipei**

![](_page_32_Picture_143.jpeg)

## **Table 3. Allen-Cady multivariate analysis**

\*Education: college or higher, BMI: Body mass index

\*\* Effect modification between antibody titers, vaccination and Asian; adjusted for age and

![](_page_33_Picture_139.jpeg)

d eduation in model 1; age, eduation, steroid usage and employment in model 2; male, educatio

![](_page_34_Picture_79.jpeg)

n in model 3; and BMI, chills and HIV or AIDS in model

![](_page_35_Picture_292.jpeg)

#### **Supplementary Table 1: Influenza A virus strains and assoicated GenBank accession numbers**

![](_page_36_Picture_306.jpeg)

A/Taipei/0067/2016 6B.2 KY487709

![](_page_38_Picture_355.jpeg)

**Supplementary Table 2. Clinical and demographic characteristics of H1N1 IAV-infected patients at Baltimore and Taipei based on HA clade**